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CONCISE COMMUNICATION
Mx2 expression is associated with reduced
susceptibility to HIV infection in highly exposed
HIV seronegative Kenyan sex workers
Derek R. Steina,e, Souradet Y. Shawb, Lyle R. McKinnond, Max Aboue,
Stuart J. McCorristerf, Garrett R. Westmacottf, Keith R. Fowkea,
Francis A. Plummera and T. Blake Balla, e,c
Introduction: Recent studies have identified Mx2 as a novel HIV-1 innate restriction
factor that inhibits proviral integration. A pilot proteomic study of immune cells from
highly exposed HIV-seronegative (HESN) individuals enrolled in the Pumwani sex
worker cohort identified Mx1 as potential correlate of HIV protection. A detailed
population level analysis of Mx1 and Mx2 expression and their role in reduced
susceptibility to HIV infection in HESN women was conducted.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from 102 HESN
women and 100 high-risk negative controls enrolled in a Nairobi-based sex worker
cohort. Whole-cell lysates were prepared and analyzed for Mx1 and Mx2 expression by
commercial ELISA. Bivariate and multiple linear regression analyses were conducted to
account for confounding epidemiological factors.
Results: Mx2, but not Mx1, was found to be significantly overexpressed in HESN
women compared with high-risk negative controls (P¼0.027). After multiple linear
regression analysis, accounting for age, menopause, pregnancy, Depo-Provera (Pfizer,
New York, USA) use, recent infections and medication usage, Mx2 expression remained
significantly overexpressed in the PBMC of HESN women (P¼0.05). Additionally, an
interaction model analysis indicated that HESN women who use Depo-Provera (Pfizer,
New York, USA) have 2.6-fold higher levels of Mx2 than any other group (P<0.001).
No associations with Mx1 expression were observed.
Conclusion: This is the first epidemiological report ofMx2 and its associationwith altered
susceptibility to HIV infection in HESN women. Additionally, we show that HESN women
who use Depo-Provera (Pfizer, New York, USA) have the highest levels of Mx2 expres-
sion, highlighting a possible mechanism for hormonal modulation of HIV susceptibility.
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Introduction
We have previously described a cohort of highly exposed
HIV-seronegative (HESN) sex workers from Nairobi,
Kenya, who can be epidemiologically defined as relatively
resistant to HIV infection [1]. The phenotype of these
HESN women has been shown to associate with altered
interferon signaling mediated impart by interferon
regulatory transcription factor-1 [2], T-cell immune
quiescence [3], and using unbiased proteomic techniques,
the altered expression of antiproteases in genital secretions
[4,5]. However, a proteomics analysis of mucosal and
systemic immune cells in the context of this rare
phenotype has yet to be undertaken. In a pilot proteomics
study of peripheral blood mononuclear cells (PBMC)
isolated from HESN (n¼ 12) and HIV-susceptible
controls (n¼ 18), we identified decreased expression of
Mx1 (P¼ 0.029) as a potential marker of HIV
susceptibility in HESN women (Fig. 1a). Validation of
Mx1 by western blot and correlation analysis (r¼ 0.6772,
P¼ 0.0001) confirmed the lower Mx1 expression in the
same HESN samples (Fig. 1b and c). The reduced
expression of Mx1, and possibly other members of this
family in HESN women, may reflect the altered
interferon responsiveness previously observed in these
individuals [6]. Additionally, recent studies have shown
that Mx2 is a correlate of simian immunodeficiency virus
(SIV) protection in macaques [7], restricts HIV-1
infection in vitro [8–10], and is likely due to the
destabilization of viral replication complexes or nuclear
import [11]. Although Mx2 was not differentially
regulated in our initial pilot data (Fig. 1a), these recent
studies and the similar amino acid homology between the
two proteins (63%), led us to conduct a more detailed
population level analysis of Mx1 and Mx2 expression in
HESN women from the Pumwani sex worker cohort.
Results
To determine the expression levels of Mx1 and Mx2 in a
larger study accounting for epidemeological covariates,
we isolated PBMC from 102 HESN women meeting our
epidemiologic definition of HIV resistance and 100 high-
risk HIV-susceptible female sex workers (HIV-S). HESN
women are epidemiologically defined as being active in
sex work while remaining HIV negative (serology and
PCR) for 7 years or longer. Given the volume of clients,
the estimated prevalence of HIV in this population, and
duration of seronegative follow-up, it is clear these
individuals have intense exposure to HIV. A commercial
ELISA was used to measure the levels of Mx1 and Mx2 in
PBMC lysate from the two study groups. Bivariate
comparisons indicated that the Mx1 expression in PBMC
was similar between HESN women and HIV-S controls
(Fig. 1d, P¼ 0.169), clearly in disagreement with our
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Fig. 1. Expression of Mx1 and Mx2 in highly exposed HIV-seronegative women. (a) Protein biomarkers of interest differentially
regulated between highly exposed HIV-seronegative (HESN) and HIV-susceptible controls (P< 0.05 and a FC >1.5). (b)
Representative western blot analysis at the patient level with an HIV-infected individual included for comparative purposes
and (c) correlation between the mass spectrometry and western blot expression. Expression levels are illustrated for (d) Mx1 and (e)
Mx2 measured by commercial ELISA in 102 HESN and 100 HIV-susceptible controls. (f) Bivariate analysis of epidemiological
factors with respect to log Mx2 expression, excluding pregnant and postmenopausal women.
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proteomics pilot study. These discrepancies highlight the
issues associated with accurately controlling for epide-
miological confounders in proteomics or other systems
biology approaches that are often found in small-scale
human studies. Surprisingly, in contrast, Mx2 expression
was found to be elevated in HESN women (P¼ 0.029)
compared to HIV-S controls (Fig. 1e). Univariate analysis
of epidemiologic confounders in these women showed
factors such as age, duration of sex work, a break from sex
work, and recent infections or medication use did not
affect the expression of Mx2 (Fig. 1f) or Mx1 (Suppl.
Table 1, http://links.lww.com/QAD/A590). However,
when we examined contraception use, we found that
women who reported using injectable Depo-Provera
(DMPA; Pfizer, New York, USA) had significantly higher
expression of Mx2 (Fig. 1f; P¼ 0.005) compared with
those who did not use DMPA.
To better define the relationship between DMPA use and
systemic cellular expression of Mx1 and Mx2, multiple
linear regression analysis was conducted to account for
epidemiological confounders. In a multiple linear
regression model adjusted for DMPA use, age, and
current infections, the increased Mx2 expression
associated with HESN women remained significant
(Fig. 2a; P¼ 0.05; model 3). An interaction indicator
model between DMPA use and HESN status was also
tested (Fig. 2a, model 4), and found that HESN women
who use DMPA accounted for the majority of increased
Mx2 expression observed in this group. The mean Mx2
expression in the PBMC of HESN women reporting
DMPA use was on average 2.6-fold higher (1.35 rg/mg of
PBMC lysate) than any other group (Fig. 2c; P< 0.0001).
Using the same linear regression analysis and interaction
model no significant relationships for Mx1 were noted
(Fig. 2b & Suppl. Table 2, http://links.lww.com/QAD/
A590). Together these findings suggest an association
between the HESN phenotype, DMPA use, and Mx2,
but not Mx1 expression.
Methods
Cohort participants
The Pumwani sex worker cohort is an open cohort that
provides HIV-1 prevention services and treatment
through funding from the Presidents Emergency Plan
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HESN vs. HIV-S (ref)
Depo-provera (DMPA)
Age: 35–39 years (<35 years as ref)
Age: 40+ years (<35 years as ref)
Recent infection, last 2 months
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Fig. 2. DMPA use and its effect on Mx1/Mx2 expression in highly exposed HIV-seronegative women. (a) Linear regression
modeling accounting for DMPA, age, recent infection, and the DMPA interaction with respect to Mx2 expression in HESN women
compared with HIV-susceptible controls. The expression of Mx1 (b) and Mx2 (c) in highly exposed HIV-seronegative (HESN) and
HIV-susceptible women with reported DMPA use. P<0.05, P0.01.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
For AIDS Relief. The cohort has enrolled over more than
3800 female sex workers, with approximately 250 new
enrolments per year. These women are at extremely high
risk of HIV-1 infection, with 50% of women being
HIV-1 seropositive at enrollment. This cohort includes
1285 women in active follow-up, with 671 infected and
614 uninfected, of which 107 HESN participants
meet our epidemiologic definition of resistance to HIV
(HIV-R) infection (>7 years in the cohort, active in
sex work, and HIV-1 negative by ELISA and DNA/RNA
testing). Women who are newly enrolled in the cohort,
with 3 years or less of follow-up (HIV-S) are considered to
be at the same risk of acquiring HIV infection as HIV-R
women and act as an HIV-S control. Based upon 27 years
of epidemiologic follow-up, we expect 85% of the HIV-S
to seroconvert, despite strong HIV-1 prevention pro-
grammes. Both HIV-R and HIV-S have similar numbers
of clients per day, as well as reported condom use with
casual and regular clients. Written informed consent was
obtained from all study participants of the Pumwani
cohort. Approval for all studies was obtained from the
research ethics board of the University of Manitoba,
Winnipeg, Canada and the Kenyatta National Hospital,
Nairobi, Kenya.
Sample preparation
PBMC were isolated for the pilot mass spectrometry and
epidemiological studies by density gradient centrifu-
gation (Ficoll-Paque). PBMC samples for the epidemio-
logical studies conducted on Mx1 and Mx2 in the
Pumwani cohort were isolated in Nairobi, Kenya, from
1995 to 2009. Sample storage length was found not to
have any effect on Mx1/2 protein expression as well as cell
viability by correlation analysis. PBMC were frozen in
freezing media and shipped back to Winnipeg, Manitoba,
Canada, and stored in liquid nitrogen. PBMCs were
removed from the liquid nitrogen tank and rapidly thawed
in a 378C water bath. Cells were transferred from the
cryovial and immediately placed in 10 ml of RPMI
supplemented with 10% fetal calf serum, penicillin,
streptomycin, and fungizone (Life Technologies, Carls-
bad, California, USA). Cell viability and counts were
conducted on each sample to ensure a viability of at least
80% using the Invitrogen Countess Automated Cell
Counter (Carlsbad, California, USA) by trypan blue
staining. After counting, the cells were centrifuged at
800 g for 10 min. Cells were washed in PBS three times.
Cells were then resuspended in either 200 ml of 4% SDS
(MS analysis) or 500 ml of PBS (ELISA analysis). PBMCs
suspended in PBS were subjected to three rapid freeze
thaw cycles on dry ice. The resulting PBMC lysate was
centrifuged at 1500 g to remove any excess cellular debris.
PBMCs suspended in 4% SDS were immediately boiled
for 5 min followed by centrifugation at 1500 g to remove
any excess cellular debris. PBMC lysate was transferred to
a new cryovial and stored at808C for future use by mass
spectrometry or ELISA analysis. The total protein
concentration of PBMC lysate in 4% SDS and PBS
was determined by 2D-Quant (GE Healthcare, Chalfont,
UK) and BCA assay (Millipore, Billerica, Massachusetts,
USA), respectively.
Isobaric tags for relative and absolute
quantitation mass spectrometry
Trypsin digestion of PBMC lysate in 4% SDS was
performed by the filter-aided sample preparation method
[12] with modifications, briefly described as follows:
approximately 500 mg of protein per digestion was mixed
with 7 its volume in urea exchange buffer, then passed
through a 10 kDa Nanosep spin filter (Pall Corp., Port
Washington, New York, USA). Two additional washes
with UEB were performed to remove excess SDS.
Protein was then alkylated with 50 mmol/l iodoaceta-
mide for 20 min at room temperature in the dark. Filters
were washed twice with UEB, treated with 1000 units of
benzonase (Novagen, Madison, Wisconsin, USA) in
50 mmol/l Tris or 50 mmol/l HEPES for 30 min at room
temperature, then rinsed again with Tris or HEPES
buffer. Each filter was treated with 1.5 mg of trypsin gold
(Promega, Madison, Wisconsin, USA) per 100 mg
protein overnight at 378C. Filter cartridges were inverted
and the peptides were spun off the filter with three washes
of 50 mmol/l Tris or HEPES. Peptides were lyophilized,
resuspended in water, and quantified by ultraviolet
absorbance at 280 nm. Samples were then frozen at
808C for future analysis or processing. When isobaric
tags for relative and absolute quantitation (iTRAQ)
labeling was required, digested peptides were resuspended
in 30 ml of 100 mmol/l HEPES. The contents of a single
iTRAQ reagent tube (AB Sciex, Framingham, Massa-
chusetts, USA) were resuspended in 70 ml of ethanol and
added to the peptides. The pH of each reaction was
verified and adjusted to pH 8 if necessary for optimal
labeling efficiency. After labeling, 100 ml of H2O was
added to quench any further labeling.
In order to ensure equal, one-to-one ratios between all
iTRAQ reporter ions and verification of efficient
labeling, equal volumes (1 ml) of each labeled sample
were mixed with buffer A (2% acetonitrile, 0.1% formic
acid) to a final volume of 20 ml, and analyzed by online
nLC/MS/MS (see below). Ratios from the most
abundant proteins were then used to make minor
corrections to the final mixing volumes ensuring equal
1 : 1 ratios for all reporter channels.
Samples were multiplexed to ensure an overall 1 : 1 ratio
for all the iTRAQ reporter channels. 75 mg of peptide
was lyophilized and resuspended in 200 mmol/l
ammonium formate, pH 10 and loaded onto an offline
high-pH reversed phase column for fractionation (Waters,
Milford, Massachusetts, USA; XBridge C18 3.5mm
2.1100 mm) described previously [13]. Samples were
fractionated using an Agilent 1200 series microflow pump
(Agilent, Santa Clara, California, USA) with buffer A
(20 mmol/l ammonium formate, pH 10) and buffer B
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(90% ACN, 20 mmol/l ammonium formate, pH 10). The
samples from each patient were then generally subjected
to one of two linear gradients. A non-iTRAQ labeled
gradient (0–60% buffer B at 150 ml/min for 66 min) or a
iTRAQ specific gradient (3% B – 10 min, 8–11.5% B –
7 min, 11.5–60% B – 58 min, at 150 ml/min). A total of
24 fractions were collected over the peptide elution
profile and then concatenated into 12 final fractions.
Fractions were then lyophilized and stored at 808C for
future MS analysis.
Peptide fractions were resuspended in nano-LC buffer A
(0.1% formic acid, 2% ACN) and approximately 1.5 mg
from each fraction was injected onto a 2-cm precolumn
(id¼ 100-mm) consisting of 5-mm particle-sized
ReproSil-Pur C18- AQ resin (Dr Maisch GmbH, Beim
Bruckle, Germany). Peptides were further resolved on
a 10-cm analytical column (id¼ 75-mm) consisting of
3-mm particle-sized ReproSil-Pur C18-AQ resin (Dr
Maisch GmbH) using an Easy-nLC system (Thermo
Fisher Scientific, Waltham, Massachusetts, USA) with a
linear gradient from 0 to 40% buffer B (0.1% formic acid,
98% ACN) over 120 min at a flow rate of 300 nl/min.
The total runtime was 160 min, which included sample
loading, gradient elution, ACN wash, and column
equilibration. Mass spectra were acquired using a data-
dependent method using an Orbitrap Velos mass
spectrometer (Thermo Fisher Scientific). The top 10
abundant precursor ions from each survey scan were
isolated (2.0 m/z isolation width) and fragmented by
higher-energy collision dissociation (45% normalized
collision energy, with 100 ms activation time). The survey
scans, were acquired in the Orbitrap using a mass window
of 300–1700 m/z at a target resolution of 60 000, at
400 m/z, and the subsequent fragment ion scans were
acquired over a dynamic m/z range. The lower threshold
for selecting a precursor ion for fragmentation was 1000
ions. Dynamic exclusion was enabled using a list size of
500 features, an m/z tolerance of 15 ppm, a repeat count
of 1, a repeat duration of 30 s, and an exclusion duration
of 15 s, with early expiration disabled.
RAW (Thermo Fisher) data files from the Orbitrap Velos
were processed using the Mascot search engine (v2.3
Matrix Science, London, UK). All data were searched
against the International Protein Index (IPI version 3.78;
Ingenuity IPA, Redwood City, California, USA) human
database. The following search parameters were used:
monoisotopic precursor tolerance was set to 10 ppm
while the MS/MS tolerance was set to 0.5 Da. Enzyme
specificity was set to trypsin with a maximum of one
missed cleavage. Carbamidomethyl of cysteine, iTRAQ
labeling of N-termini and lysine’s were all applied as fixed
modifications. Oxidation of methionine, and iTRAQ
labeling of tyrosine were set as variable modifications. All
donors were imported into an instance of Trans
Proteomic Pipeline implemented in Scaffold v3.4.9
(Proteome Software, Portland, Oregon, USA).
X!Tandem (thegpm.org) was used within Scaffold as
an additional measure for confident peptide and pro-
tein identifications (thegpm.org; version CYCLONE,
2010.12.01.1). Quantitative results were exported from
Scaffold with the following criteria: minimum peptide
probability of 80% (Peptide Prophet; Protein & Peptide
Prophet, Seattle, Washington, USA) a minimum protein
probability of 99% (Protein Prophet), and a minimum of
two peptides per protein. These setting resulted in a 0.1%
protein and 1.5% peptide false discovery rate for the entire
dataset. Statistical significance between the respective
study groups was evaluated using a Student’s t-test for
each protein comparison.
Western blot analysis
PBMC lysate (25 mg) was loaded on to a NuPAGE
4–12% Bis-Tris precast acrylamide gel (Life Techno-
logies). Affinity MagicMarkTM XP (Life Technologies)
was also loaded as molecular weight marker. Gels were
resolved to completion using an XCell SureLock Mini-
Cell (Invitrogen, Carlsbad, California, USA) electro-
phoresis tank running at 150 V. After protein gel
electrophoresis, proteins were transferred onto a nitro-
cellulose membrane using the Invitrogen iBlot (Invitro-
gen) transfer system. Membranes were directly placed in
Odyssey blocking buffer (OBB; LI-CORE) for 1 h at
room temperature with gentle mixing. Primary anti-
bodies Mx1, RGS6, and HLA-C (Epitomics) were
diluted in OBB with the addition of 0.1% Tween-20
(Sigma) and incubated overnight at 48C on an orbital
shaker. An antibody loading control (b-Actin; Abcam)
incubated for 1 h at room temperature followed by four
5-min washes with phosphate-buffered saline–Tween
(PBS, 0.1% Tween-20). Secondary fluorescent antibodies
(IRDye 680R/800CW, diluted in OBB, 0.1% Tween 20,
and 0.01% SDS; LI-CORE) were then incubated at room
temperature for 1 h in the dark followed by another four
5-min washes with PBST. A final wash of PBS for 5 min
was performed. Blots were subsequently dried at 48C and
imaged using an Odyssey CLx infrared imagining system
(LI-CORE).
Mx1 and Mx2 ELISA
A commercial ELISA was purchased from USCN Life
Science Inc. (Wuhan, China) for the quantification of
Mx1 and Mx2 in PBMC lysate. Briefly, a standard
doubling dilution series was prepared for either Mx1 or
Mx2 (20–0.02 ng/ml) and PBMC lysate samples in PBS
from each study participant were added to the plates in
duplicate. The plates were sealed and incubated for 2 h at
378C. After incubation the samples and standard curve
were aspirated from the plate using the Bioteck plate
washer. A biotin-conjugated antibody specific for Mx1 or
Mx2 was added (1 : 100 dilution) followed by incubation
at 378C for 60 min. After incubation the plates were
manually washed three times with the wash buffer
provided in the ELISA kit. A secondary avidin conjugated
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to horseradish peroxidase was then added (1 : 100
dilution) and incubated for 30 min at 378C. The plates
were again washed five times with the provided wash
buffer. Tetramethylbenzidine substrate was then added to
the plates and incubated at 378C for 15–30 min. Stop
solution (sulphuric acid) was then added to terminate the
reaction. The plates were read using the SpectraMax Plus
spectrophotometer at a wavelength of 450 nm. A four-
parameter curve was used to fit the standard curve for
accurate quantitation of Mx1 and Mx2.
Epidemiological analysis
The Mx1 and Mx2 expression levels measured by the
commercial ELISA were transformed using their natural
logarithms. The log-transformed values of Mx1 and Mx2
were subsequently used as outcome variables in separate
multiple linear regression models. Where appropriate, t-
tests and ANOVA’s were used in bivariate analyses with
logged values of Mx1/Mx2 used as the outcome
variables. Multiple linear regression models were fitted
to the data and used to assess the independent association
of HESN status and the logged values of Mx1 and Mx2,
adjusted for age, recent infections (2 months) and Depo-
Provera. Given their theoretical importance, all con-
founders were kept in full linear regression models;
however, each confounder was entered separately in the
following order: use of Depo-Provera, age, and recent
infection in the last 2 months. In addition, the interaction
between Depo-Provera use and HESN status was added as
an additional variable in the final full model. All tests
performed were considered statistically significant at
P< 0.05. Stata 12 (College Station, Texas, USA) was used
for all epidemiological analyses. Age, recent infections,
and Depo-Provera were included a priori due to the
impact of these variables on general immune function.
The interaction between HESN status and Depo-Provera
was also planned a priori due to our interest in whether or
not levels of Mx1/Mx2 between HESN and high-risk
negative controls differed by use of Depo-Provera. From
an initial sample of 202 women, 190 had detectable levels
for both Mx1 and Mx2. For all models, menopausal
(n¼ 2), pregnant (n¼ 5) and missing values for contra-
ception use (n¼ 22) were excluded from the analyses,
leaving a total sample size of 161 women.
Discussion
Although still controversial [14], several studies have
linked DMPA use with increased risk of HIV acquisition
[15,16]. These studies suggest that HESN women using
DMPA are likely at a higher risk of infection than HESN
women who do not use DMPA. The high levels of Mx2
observed in HESN women, epidemiologically resistant to
HIV, may provide a plausible biologic mechanism to
explain how this particular subset of HESN women is
protected from infection. DMPA is commonly used in
sub-Saharan Africa and represents a relatively inexpensive
alternative to oral or intrauterine device contraception.
For this reason, it is possible that DMPA use could be
confounded by some other epidemiological factor not
captured in our study. However, given that DMPA has
been shown to suppress interferon responses, and that
interferon-stimulated genes, such as Mx2, have been
associated with protection from SIV infection in rhesus
macaques, a biological interaction between DMPA and
Mx2 in HESN women is plausible [17,18]. Although it is
tempting to suggest that DMPA alone could be used to
modulate resistance, its broad immunosuppressive effects
and reported increase in HIV acquisition risk will most
likely eliminate its use in preventive strategies. However,
identification of an intermediate biologic link between
DMPA and innate Mx2 signaling in HESN women may
allow for targeted regulation of Mx2 as a novel prevention
strategy. Interventions such as RNA interference of
known regulators of Mx2 or through as yet defined viral/
host mRNA mechanisms could alternatively be used to
regulate HIV resistance and susceptibility via Mx2. Data
from our group and others have shown that the HESN
phenotype is multifactorial; however, one commonality is
the altered expression of innate factors limiting HIV
replication, immune activation, and the recruitment of
target cells [3]. Increased expression of Mx2 in HESN
women using DMPA may suggest a link to this immune
quiescent phenotype; however, a causal relationship
between altered interferon signaling and the genetic
regulation of Mx2, influenced by hormonal contra-
ception, needs to be established. One recent study has
suggested that Mx2 expression of injection drug users and
sexually exposed HIV individuals may play a role in
altered susceptibility to HIV infection [19]. Thus, further
studies of the relationship between HIV susceptibility,
Mx2 expression, and DMPA use are clearly warranted.
These data represent the first report of Mx2 as a
contributor to altered susceptibility to HIV infection in
HESN female sex workers in the context of epidemio-
logic confounders such as hormonal contraception use.
Future studies need to identify mechanisms that may
regulate higher expression of Mx2 in HESN women and
its interaction with DMPA. A deeper understanding of
interferon responses to HIV in the real-world setting
could lead to HIV preventative measures that make use of
Mx2 to modulate resistance and susceptibility to HIV
infection.
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